# Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)

> **NCT00322361** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 566 (actual)

## Conditions studied

- Hepatitis B
- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Comparator: RECOMBIVAX HB™
- **BIOLOGICAL:** Comparator: Modified process Hepatitis B Vaccine

## Key facts

- **NCT ID:** NCT00322361
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 566 (ACTUAL)
- **Last updated:** 2017-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322361, "Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00322361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*